This is my last point.
I just want to stress, as you've heard from several witnesses before this committee, that however important—and perhaps essential—post-market surveillance and vigilance is, it is not a substitute for due diligence pre-market. It would not be acceptable to lower the bar before medicines come to market simply because we think we have a safety net in the real world environment.
Thank you.